, Volume 12, Issue 1, pp 1-3
Date: 29 Jan 2010

Heparin and Aspirin Versus Aspirin Alone for Prevention of Recurrent Pregnancy Loss

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Laskin CA, Spitzer KA, Clark CA, et al.: Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol 2009, 36:279–287.


• Of importance


The current standard of care for the prevention of recurrent pregnancy loss in women with antiphospholipid antibodies (aPL) is treatment with heparin (unfractionated or low molecular weight) and low-dose acetylsalicylic acid (ASA; aspirin) during pregnancy. Evidence supporting the benefit of this regimen over aspirin alone largely derives from two trials published in the late 1990s [1, 2]. In 2002, however, Farquharson et al. [3] found a high live birth rate with ASA alone and no benefit from the addition of heparin. The recent study by Laskin et al. [4] is an open-label, randomized controlled trial designed to address this important clinical issue.


This study intended to compare live birth rates in women with recurrent pregnancy loss associated with aPL, coa ...